Outlook Therapeutics (OTLK) Insider Trading & Ownership → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free otlk Stock Alerts $8.43 +0.24 (+2.93%) (As of 04/26/2024 ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Outlook Therapeutics (NASDAQ:OTLK) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.30%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$22,245.24Number OfInsiders Selling(Last 12 Months)0 Get OTLK Insider Trade Alerts Want to know when executives and insiders are buying or selling Outlook Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address OTLK Insider Buying and Selling by Quarter Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. Outlook Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/28/2024Yezan Munther HaddadinDirectorBuy1,882$11.82$22,245.24 (Data available from 1/1/2013 forward) OTLK Insider Trading Activity - Frequently Asked Questions Who is on Outlook Therapeutics's Insider Roster? The list of insiders at Outlook Therapeutics includes C Russell Trenary III, Ghiath M Sukhtian, Jeff Evanson, Kurt J Hilzinger, Terry Dagnon, and Yezan Munther Haddadin. Learn more on insiders at OTLK. What percentage of Outlook Therapeutics stock is owned by insiders? 5.30% of Outlook Therapeutics stock is owned by insiders. Learn more on OTLK's insider holdings. Which Outlook Therapeutics insiders have been buying company stock? The following insiders have purchased OTLK shares in the last 24 months: C Russell Trenary III ($21,115.20), Kurt J Hilzinger ($87,908.80), Terry Dagnon ($10,500.00), and Yezan Munther Haddadin ($26,817.24). How much insider buying is happening at Outlook Therapeutics? Insiders have purchased a total of 7,120 OTLK shares in the last 24 months for a total of $146,341.24 bought. Which Outlook Therapeutics insiders have been selling company stock? The following insiders have sold OTLK shares in the last 24 months: Jeff Evanson ($161,532.40), and Terry Dagnon ($592,800.00). How much insider selling is happening at Outlook Therapeutics? Insiders have sold a total of 32,520 Outlook Therapeutics shares in the last 24 months for a total of $754,332.40 sold. More Insider Trading Tools from MarketBeat Related Companies: Vigil Neuroscience Insider Trading aTyr Pharma Insider Trading bluebird bio Insider Trading BioAtla Insider Trading Sangamo Therapeutics Insider Trading Zura Bio Insider Trading Agenus Insider Trading Omega Therapeutics Insider Trading DBV Technologies Insider Trading Curis Insider Trading Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: Pagaya Technologies: An AI Fintech That Insiders Are BuyingThe 5 Stocks Most Sold By Insiders This Year3 Cheap Stocks Insiders are Buying: Investors Should Avoid 1The 5 Hottest CEO Stock Purchases So Far This Year3 Cheap Stocks that Insiders Bought in Q1 This page (NASDAQ:OTLK) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.